423
Views
39
CrossRef citations to date
0
Altmetric
Reviews

Advances in mobilization for the optimization of autologous stem cell transplantation

, , , , , , & show all
Pages 1412-1421 | Received 27 Dec 2008, Accepted 05 Jun 2009, Published online: 15 Sep 2009

References

  • Arslan O, Moog R. Mobilization of peripheral blood stem cells. Transfus Apher Sci 2007; 37: 179–185
  • Moog R. Management strategies for poor peripheral blood stem cell mobilization. Transfus Apher Sci 2008; 38: 229–236
  • Kessinger A, Armitage J O, Landmark J D, et al. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol 1986; 14: 192–196
  • Bensinger W I, Weaver C H, Appelbaum F R, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655–1658
  • Korbling M, Przepiorka D, Huh Y O, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659–1665
  • Lasky L C, Hurd D D, Smith J A, et al. Peripheral blood stem cell collection and use in Hodgkin's disease. Comparison with marrow in autologous transplantation. Transfusion 1989; 29: 323–327
  • Ottinger H D, Beelen D W, Scheulen B, et al. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996; 88: 2775–2779
  • Henon P R, Liang H, Beck-Wirth G, et al. Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant 1992; 9: 285–291
  • Cashen A F, Lazarus H M, Devine S M. Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF?. Bone Marrow Transplant 2007; 39: 577–588
  • Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?. Blood 2001; 98: 2900–2908
  • Bensinger W I, Martin P J, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175–181
  • Champlin R E, Schmitz N, Horowitz M M, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000; 95: 3702–3709
  • Berenson R J, Bensinger W I, Hill R S, et al. Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77: 1717–1722
  • Civin C I, Strauss L C, Brovall C, et al. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984; 133: 157–165
  • Siena S, Bregni M, Brando B, et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77: 400–409
  • Healy L, May G, Gale K, et al. The stem cell antigen CD34 functions as a regulator of hematopoietic cell adhesion. Proc Natl Acad Sci USA 1995; 92: 12240–12244
  • Nervi B, Link D C, DiPersio J F. Cytokines and hematopoietic stem cell mobilization. J Cell Biochem 2006; 99: 690–705
  • Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999; 283: 845–848
  • Levesque J P, Sims N A, Bendall L J, et al. Endosteal niches and lymphopoiesis are inhibited during G-CSF induced hematopoietic stem cell mobilization. Blood 2008; 112: 320a
  • Richman C M, Weiner R S, Yankee R A. Increase in circulating stem cells following chemotherapy in man. Blood 1976; 47: 1031–1039
  • Olavarria E, Kanfer E J. Selection and use of chemotherapy with hematopoietic growth factors for mobilization of peripheral blood progenitor cells. Curr Opin Hematol 2000; 7: 191–196
  • Ballestrero A, Ferrando F, Garuti A, et al. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF. J Clin Oncol 1999; 17: 1296
  • Gojo I, Guo C, Sarkodee-Adoo C, et al. High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity. Bone Marrow Transplant 2004; 34: 69–76
  • To L B, Shepperd K M, Haylock D N, et al. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 1990; 18: 442–447
  • Pusic I, Jiang S Y, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008; 14: 1045–1056
  • Gianni A M, Siena S, Bregni M, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; 2: 580–585
  • Socinski M A, Cannistra S A, Elias A, et al. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988; 1: 1194–1198
  • Lane T A, Law P, Maruyama M, et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995; 85: 275–282
  • Montgomery M, Cottler-Fox M. Mobilization and collection of autologous hematopoietic progenitor/stem cells. Clin Adv Hematol Oncol 2007; 5: 127–136
  • Cashen A F, Nervi B, DiPersio J. AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent. Future Oncol 2007; 3: 19–27
  • Copelan E A. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813–1826
  • Semerad C L, Christopher M J, Liu F, et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 2005; 106: 3020–3027
  • Levesque J P, Liu F, Simmons P J, et al. Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood 2004; 104: 65–72
  • Amgen. Neupogen full prescribing information, Available online at: http://www.amgen.com/pdfs/misc/neupogen_pi.pdf, accessed 25 June 2008
  • Fischmeister G, Gadner H. Granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor for collection of peripheral blood progenitor cells from healthy donors. Curr Opin Hematol 2000; 7: 150–155
  • Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547–2555
  • Watts M J, Addison I, Ings S J, et al. Optimal timing for collection of PBPC after glycosylated G-CSF administration. Bone Marrow Transplant 1998; 21: 365–368
  • Stroncek D F, Matthews C L, Follmann D, et al. Kinetics of G-CSF-induced granulocyte mobilization in healthy subjects: effects of route of administration and addition of dexamethasone. Transfusion 2002; 42: 597–602
  • Koenigsmann M, Jentsch-Ullrich K, Mohren M, et al. The role of diagnosis in patients failing peripheral blood progenitor cell mobilization. Transfusion 2004; 44: 777–784
  • Visani G, Lemoli R M, Tosi P, et al. Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. Br J Haematol 1999; 105: 775–779
  • Arbona C, Prosper F, Benet I, et al. Comparison between once a day vs. twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC transplantation. Bone Marrow Transplant 1998; 22: 39–45
  • Kroger N, Zeller W, Hassan H T, et al. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 × 5 μg/kg) compared to a single dose (1 × 10 μg/kg). Bone Marrow Transplant 1999; 23: 125–129
  • Kroger N, Renges H, Kruger W, et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 2000; 111: 761–765
  • Kroger N, Sonnenberg S, Cortes-Dericks L, et al. Kinetics of G-CSF and CD34+ cell mobilization after once or twice daily stimulation with rHu granulocyte-stimulating factor (lenograstim) in healthy volunteers: an intraindividual crossover study. Transfusion 2004; 44: 104–110
  • Amgen. Neulasta full prescribing information, Available online at: http://www.amgen.com/pdfs/misc/neulasta_pi.pdf, accessed 25 June 2008
  • Kroschinsky F, Holig K, Ehninger G. The role of pegfilgrastim in mobilization of hematopoietic stem cells. Transfus Apher Sci 2008; 38: 237–244
  • Bruns I, Steidl U, Kronenwett R, et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 2006; 46: 180–185
  • Steidl U, Fenk R, Bruns I, et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2005; 35: 33–36
  • Devine S M, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008; 112: 990–998
  • DiPersio J, Stadtmauer E A, Nademanee A P, et al. A phase III, multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (Plerixafor)+G-CSF vs. G-CSF+placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood 2007; 110(Suppl)445, (Abstract)
  • DiPersio J F, Micallef I, Stiff P J, et al. A phase III, multicenter, randomized, double-blind, placebo controlled, comparative trial of AMD3100 (Plerixafor)+G-CSF vs. placebo+G-CSF in non-Hodgkin's lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood 2007; 110(Suppl)601, (Abstract)
  • Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41: 331–338
  • Micallef I, Stiff P J, DiPersio J F, et al. Successful stem cell mobilization rescue by AMD3100 (Plerixafor)+G-CSF for patients who failed primary mobilization: results from the phase III (3101-NHL) study. Blood 2007; 110(Suppl)602, (Abstract)
  • Anderlini P, Przepiorka D, Seong D, et al. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion 1996; 36: 590–595
  • Devine S M, Andritsos L, Todt L, et al. A pilot study evaluating the safety and efficacy of AMD3100 for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells in patients with advanced hematological malignancies. Blood 2005; 106(Suppl)299, (Abstract)
  • Bayer HealthCare. Leukine prescribing information, Available online at: http://www.leukine.com/hcp/index.jsp, accessed 9 March 2009
  • Devine S M, Brown R A, Mathews V, et al. Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone. Bone Marrow Transplant 2005; 36: 531–538
  • Hendrix C W, Collier A C, Lederman M M, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004; 37: 1253–1262
  • Flomenberg N, Devine S M, Dipersio J F, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867–1874
  • Platzbecker U, Prange-Krex G, Bornhauser M, et al. Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs. Transfusion 2001; 41: 184–189
  • Stroncek D, Shawker T, Follmann D, et al. G-CSF-induced spleen size changes in peripheral blood progenitor cell donors. Transfusion 2003; 43: 609–613
  • Stroncek D F, Dittmar K, Shawker T, et al. Transient spleen enlargement in peripheral blood progenitor cell donors given G-CSF. J Transl Med 2004; 2: 25
  • Falzetti F, Aversa F, Minelli O, et al. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 1999; 353: 555
  • Balaguer H, Galmes A, Ventayol G, et al. Splenic rupture after granulocyte-colony-stimulating factor mobilization in a peripheral blood progenitor cell donor. Transfusion 2004; 44: 1260–1261
  • Lindemann A, Rumberger B. Vascular complications in patients treated with granulocyte colony-stimulating factor (G-CSF). Eur J Cancer A 1993; 29: 2338–2339
  • Hsia C C, Linenberger M, Mangel J, et al. Acute myeloid leukemia in a healthy hematopoietic stem cell donor following past exposure to a short course of G-CSF. Bone Marrow Transpl 2008; 42: 431–432
  • Peters W P, Rosner G, Ross M, et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709–1719
  • Weaver C H, Schulman K A, Wilson-Relyea B, et al. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. J Clin Oncol 2000; 18: 43–53
  • Gazitt Y. Comparison between granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the mobilization of peripheral blood stem cells. Curr Opin Hematol 2002; 9: 190–198
  • Spitzer G, Adkins D, Mathews M, et al. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy. Bone Marrow Transplant 1997; 20: 921–930
  • Ravagnani F, Siena S, Bregni M, et al. Large-scale collection of circulating haematopoietic progenitors in cancer patients treated with high-dose cyclophosphamide and recombinant human GM-CSF. Eur J Cancer 1990; 26: 562–564
  • Narayanasami U, Kanteti R, Morelli J, et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001; 98: 2059–2064
  • Bourhis J H, Bouko Y, Koscielny S, et al. Relapse risk after autologous transplantation in pateints with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized trial. Haematologica 2007; 92: 1083–1090
  • Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002; 30: 973–981
  • Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002; 3: 687–694
  • Plerixafor: AMD 3100, AMD3100, JM 3100, SDZ SID 791. Drugs R D 2007; 8: 113–119
  • De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov 2003; 2: 581–587
  • Shepherd R M, Capoccia B J, Devine S M, et al. Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100. Blood 2006; 108: 3662–3667
  • Larochelle A, Krouse A, Metzger M, et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 2006; 107: 3772–3778
  • Hess D A, Bonde J, Craft T P, et al. Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor. Biol Blood Marrow Transplant 2007; 13: 398–411
  • Devine S M, Flomenberg N, Vesole D H, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 1095–1102
  • Drug.com Web site. Mozobil: Genzyme files applications for approval of mozobil in the United States and Europe. Available online at: http://www.drugs.com/nda/mozobil_080617.html, accessed 25 June 2008
  • Uy G L, Rettig M P, Ramirez P, et al. Kinetics of human and murine mobilization of acute myeloid leukemia in response to AMD 3100. Blood 2001; 110: 867a
  • Runnels J M, Azab A, Pitsillides C, et al. In vivo mobilization of multiple myeloma cells out of the bone marrow using the CXCR4 inhibitor AMD 3100 and Bortezomib: implications for sensitivity of myeloma cells to apoptosis. Blood 2007; 110(Suppl)2501a, (Abstract)
  • Azab A K, Runnels J M, Pitsillides C, et al. The CXCR4 Inhibitor AMD 3100 disrupts the interaction of multiple myeloma cells and the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009; 113: 4241–4257
  • Burger J A, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009; 23: 43–52
  • Desikan K R, Tricot G, Munshi N C, et al. Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol 2001; 112: 242–247
  • Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588–596
  • Bensinger W I, Longin K, Appelbaum F, et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825–831
  • Negrin R S, Kusnierz-Glaz C R, Still B J, et al. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood 1995; 85: 3334–3341
  • Jillella A P, Ustun C. What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant?. Stem Cells Dev 2004; 13: 598–606
  • Gandhi M K, Jestice K, Scott M A, et al. The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplant 1999; 23: 9–13
  • Glaspy J A, Shpall E J, LeMaistre C F, et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997; 90: 2939–2951
  • Ketterer N, Salles G, Raba M, et al. High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91: 3148–3155
  • Weaver C H, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961–3969
  • Siena S, Schiavo R, Pedrazzoli P, et al. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360–1377
  • Zaucha J M, Gooley T, Bensinger W I, et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98: 3221–3227
  • Ninan M J, Flowers C R, Roback J D, et al. Posttransplant thrombopoiesis predicts survival in patients undergoing autologous hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2007; 13: 895–904
  • Sola C, Maroto P, Salazar R, et al. Bone marrow transplantation: prognostic factors of peripheral blood stem cell mobilization with cyclophosphamide and filgrastim (r-metHuG-CSF): the CD34+ cell dose positively affects the time to hematopoietic recovery and supportive requirements after high-dose chemotherapy. Hematology 1999; 4: 195–209
  • Dreger P, Kloss M, Petersen B, et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995; 86: 3970–3978
  • Weaver C H, Schwartzberg L S, Birch R, et al. Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide, and granulocyte-colony-stimulating factor: an analysis of 497 patients. Transfusion 1997; 37: 896–903
  • Haas R, Mohle R, Fruhauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787–3794
  • Kasparu H, Krieger O, Girschikofsky M, et al. Factors influencing the timing of peripheral blood stem cell collection (PBSC). Transfus Sci 1996; 17: 595–600
  • Anderlini P, Przepiorka D, Seong C, et al. Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion 1997; 37: 507–512
  • de la Rubia J, Arbona C, de Arriba F, et al. Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. Transfusion 2002; 42: 4–9
  • Neben S, Hellman S, Montgomery M, et al. Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents. Exp Hematol 1993; 21: 156–162
  • Schmidt-Hieber M, Busse A, Reufi B, et al. Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro. J Cancer Res Clin Oncol 2009; 135: 227–234
  • Kumar S, Dispenzieri A, Lacy M Q, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21: 2035–2042
  • Mazumder A, Kaufman J, Niesvizky R, et al. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 2008; 22: 1280–1281, author reply 1281–1282
  • Paripati H, Stewart A K, Cabou S, et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008; 22: 1282–1284
  • GlaxoSmithKline. Bexxar complete prescribing information. Available online at: http://us.gsk.com/products/assets/us_bexxar.pdf, accessed 17 April 2008
  • Cell Therapeutics Inc. Available online at: http://www.zevalin.com/pdf/Zevalin_PI_website.pdf, accessed 17 April 2008
  • Zhang M M, Gopal A K. Radioimmunotherapy-based conditioning regimens for stem cell transplantation. Semin Hematol 2008; 45: 118–125
  • Vose J M, Sharp G, Chan W C, et al. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol 2002; 20: 2344–2352
  • Kessinger A, Armitage J O, Smith D M, et al. High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 1989; 74: 1260–1265
  • Chao N J, Schriber J R, Grimes K, et al. Granulocyte colony-stimulating factor “mobilized” peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031–2035
  • To L B, Roberts M M, Haylock D N, et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277–284
  • Bensinger W, Singer J, Appelbaum F, et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993; 81: 3158–3163
  • Gazitt Y, Freytes C O, Akay C, et al. Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients. Stem Cells Dev 2007; 16: 657–666
  • Gazitt Y, Akay C, Thomas C, III. No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-Hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF. Stem Cells Dev 2006; 15: 269–277

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.